Interferon alpha hybrid - Alfacyte

Drug Profile

Interferon alpha hybrid - Alfacyte

Latest Information Update: 29 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Strathclyde
  • Developer Alfacyte; University of Edinburgh
  • Class Antiallergics; Antineoplastics; Interferons; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors; Interleukin-22 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; Food hypersensitivity

Highest Development Phases

  • Research Cancer; Food hypersensitivity; Psoriasis

Most Recent Events

  • 29 May 2017 Alfacyte has patent protection for interferon alpha hybrid in USA
  • 29 May 2017 Early research in Cancer in United Kingdom (PO) before May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top